Nutritional targeting compositions that release sulforaphane and uses thereof
The composition of sulforasulfide, myrosinase and α-cyclodextrin is used to generate and integrate sulforaphane, which solves the problems of instability and irritation of sulforaphane, and achieves its effective release and stable storage, reducing the Stimulation to the human body.
Patent Information
- Application Number
- CN202411066339.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
AI Technical Summary
In the prior art, sulforaphane is unstable and difficult to preserve, and its precursor substances radish sulforin and melaninase stimulate the human stomach when used, affecting compliance.
Using a composition of sulforasulfide, myrosinase and α-cyclodextrin, sulforaphane is generated through hydrolysis reaction, and irritation is avoided through the inclusion of α-cyclodextrin, forming a solid nutrient target without irritation. Composition.
It realizes the effective release and stable storage of sulforaphane, reduces the irritation to the oral and stomach, and improves the application compliance of the product.
Smart Images

Figure SMS_1 
Figure SMS_2
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine and relates to a nutritional targeted composition for releasing sulforaphane and application of the composition. Background Art
[0002] As people's diet and living habits change, the number of patients with chronic non-communicable diseases in various countries continues to increase, and the coexistence of multiple diseases is becoming more serious. Chronic diseases are one of the main causes of morbidity and mortality in the world, posing a huge threat to human life and health.
[0003] Precision nutrition, or nutritional targeting, is an important idea for the chemical prevention of chronic diseases. Nutritional targeting is a goal proposed based on the theory of nutritional genomics. One of the main ideas of nutritional targeting is to use the active ingredients in dietary supplements such as broccoli (such as glucoraphanin and sulforaphane) to activate the Nrf2 (NF-E2-related factor 2, a transcription factor that regulates the cell's antioxidant stress response) pathway and promote the expression of phase II enzymes, thereby achieving the corresponding effect. Based on the activation effect of the Nrf2 pathway, it can play a therapeutic and preventive role in gastric ulcers and Helicobacter pylori infection, as well as a variety of diseases including diabetes, cardiovascular disease, Helicobacter pylori infection, autism, schizophrenia, depression, Alzheimer's disease, etc.
[0004] Sulforaphane (SFN) is chemically named 1-isothiocyanate-4-methylsulfonylbutane, also known as sulforaphane. It belongs to the class of isothiocyanates and is a bioactive substance found in broccoli that has the ability to prevent cancer. It is the strongest anti-cancer ingredient found in vegetables so far. The results of molecular mechanism studies and cell experiments on sulforaphane show that sulforaphane can activate the expression of genes related to human antioxidant capacity and metabolic detoxification by regulating the activity of phase II enzymes and the metabolites or foreign substances of phase I enzymes, thus playing a role similar to cancer chemoprevention (Myzak MC, Dashwood RH. Cancer Lett., 2006, 233: 208-18.). Sulforaphane is an extremely effective Nrf2 inducer. Its main mechanism of action is to activate the Nrf2 signaling pathway, regulate the activity of phase II enzymes (NQO1, glutathione S-transferase, γ-glutamylcysteine synthetase, glucuronyltransferase, etc.), and regulate antioxidant response elements. The prior art discloses a variety of activities and effects of sulforaphane and its precursor compound glucoraphanin, such as the prevention of colon cancer, pancreatic cancer and gastric cancer caused by Helicobacter pylori infection (CN1935003A; CN1170472C; CN101208079B). Nrf2 is a transcription factor that regulates the expression of many detoxification and antioxidant enzymes. Sulforaphane and glucoraphanin are known to have antimicrobial activity against Gram-positive and Gram-negative bacteria and yeast. On the one hand, investigations into the molecular basis of the mechanism of action of sulforaphane have shown that sulforaphane and glucoraphanin act as antioxidants indirectly by stimulating phase II detoxification enzymes, and have been shown to have a protective effect against Parkinson's disease through a mouse model, and have diuretic, antianemic and laxative abilities. On the other hand, sulforaphane and glucoraphanin, which are sulforaphane compounds, have also been shown to have anti-ultraviolet radiation properties, thereby preventing sunburn, degeneration caused by ROS (reactive oxygen species) and the occurrence of skin cancer (Talalay P.; Fahey JW; Healy ZR; Wehage SL; Benedict AL; Min C.; Dinkova-Kostova ATPNAS, 2007, 104, 17500-17505; CN104284885B), and they also protect the body from respiratory inflammation such as asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD) (Riedl MA: Saxon A.; Diaz-Sanchez D. Clinical Immunology, 2009, 130, 244-251).In recent years, it has been demonstrated that the factor Nrf2 plays an important role in growth factor regulation, signal transduction, and tissue repair (particularly, liver regeneration induced by oxidative stress) (Beyer T. et al. The EMBO Journal, 2008, 27, 212-223).
[0005] In summary, based on the above mechanisms, it has been discovered and confirmed that sulforaphane, as an isothiocyanate, has a variety of activities and functions related to its phase II enzyme regulation and Nrf2 activation. With the continuous deepening of research, through animal experiments and clinical trials, it has been found that in addition to its role in the field of chronic disease chemoprevention, sulforaphane also has preventive and / or therapeutic effects on a variety of diseases including diabetes, cardiovascular disease, Helicobacter pylori infection, autism, schizophrenia, depression, Alzheimer's disease (AD), etc. For example, sulforaphane can reduce the amount of glycogen produced by the liver in patients with type 2 diabetes and lower the blood sugar content in patients (Axelsson AS et al. Sci Transl Med., 2017, 9(394)); it can reduce vascular inflammation in mice and prevent TNF-α-induced monocyte adhesion to primary epithelial cells (Nallasamy P et al., J Nutr Biochem., 2014, 25(8):824-33.); it can inhibit the colonization of Helicobacter pylori in the stomach of mice and humans and reduce gastric inflammation caused by infection (Yanaka A et al. Cancer Prev Res (Phila)., 2009, 2(4):353-60.); in clinical trials, it can reverse abnormal symptoms associated with autism, such as improving oxidative stress, low antioxidant capacity, inhibited glutathione synthesis, weakened mitochondrial capacity and oxidative phosphorylation, lipid peroxidation and neuroinflammation in patients (Singh K, et al., Proc Natl Acad Sci USA, 2014, 111(43):15550-5.); it can effectively improve the cognitive function of patients with schizophrenia (Shiina A, et al., Clin Psychopharmacol Neurosci., 2015, 13(1):62-7.); dietary intake of broccoli sprouts rich in sulforaphane has a preventive effect on depression (Zhang JC, et al., J Nutr Biochem., 2017, 39:134-144.); administration of sulforaphane can improve the cognitive function of the acute AD mouse model induced by β-amyloid protein (amyloid β-protein, Aβ) in the Y maze and passive avoidance behavior tests (Kim HV, et al., Amyloid., 2013, 20(1):7-12.).Compared to other direct antioxidants (where each molecule can only neutralize another free radical molecule and they are destroyed in the process), the antioxidant capacity of sulforaphane is more durable and effective because it activates genes involved in the protection against any oxidants or carcinogens (epigenetic factors) (Young-Joon S. Science. 2003, 3, 768). In addition, Han Li et al. reported the effect of sulforaphane on reducing pulmonary fibrosis through the Nrf2 pathway (Han Li, Jiang Tao, "Chinese Journal of New Drugs and Clinical Practice", 2016 No. 12). It is known that cruciferous plants are the main source of sulforaphane and its precursor compound glucoraphanin. Among cruciferous plants, broccoli (also known as green cauliflower, broccoli, etc., a plant of the genus Brassica in the family Cruciferae) is the main source of sulforaphane and its precursor compound glucoraphanin.
[0006] Cruciferous plants also contain other compounds, such as indoleglucosinolates, which are detrimental to the health of the body. These compounds not only have a weak ability to activate the detoxification system, but can also biologically activate the system of certain carcinogens. Therefore, broccoli is selected as a raw material and other unfavorable compounds are avoided as much as possible (CN1935003A).
[0007] It is known that the precursor glucoraphanin is present in relatively higher levels in broccoli seeds and sprouts (tender shoots). Even so, it is still unrealistic to consume an effective dose of sulforaphane by eating broccoli. Therefore, it is necessary to extract broccoli and realize its effective biological efficacy through its extract.
[0008] However, it is known in the prior art that sulforaphane is unstable, easily degraded, and difficult to store and use. Therefore, its precursor glucoraphanin is used in practical applications. Glucoraphanin acts as a precursor substance and has no biological activity itself. When glucoraphanin is used, myrosinase contained in cruciferous plants is required to decompose glucoraphanin so that glucoraphanin can be converted into active sulforaphane.
[0009] However, glucoraphanin itself has a bitter taste, which seriously affects the compliance of application; and sulforaphane is irritating, especially to the stomach. These have seriously affected the compliance of product application.
[0010] In particular, for the sulforaphane products used in the prior art, especially for the mixture of myrosinase and glucoraphanin raw materials (including raw materials in the form of broccoli and / or its extracts) in solid form, it produces greater irritation in the human oral cavity and stomach, especially the stomach, when used.
[0011] Therefore, it is necessary to overcome the problem of sulforaphane products in the prior art irritating the human stomach, and it is urgently necessary to provide a composition that can effectively release sulforaphane while reducing the irritation of the product. Summary of the invention
[0012] The inventors unexpectedly discovered in a failed experiment that no unpleasant taste or smell was detected in the aqueous solution of glucoraphanin, myrosinase and α-cyclodextrin, and the presence of sulforaphane was detected. Further research unexpectedly found that when the three were placed in water, the presence of sulforaphane was detected and the problem of the unacceptable spicy taste of sulforaphane did not occur.
[0013] Without being limited by theory, the inventors speculated that when the mixture of glucoraphanin, myrosinase and α-cyclodextrin came into contact with water, a hydrolysis reaction of glucoraphanin to generate sulforaphane may occur, and a self-assembly reaction quickly occurs, i.e., the generated sulforaphane is instantly included in α-cyclodextrin, thereby avoiding the bitterness of glucoraphanin and the irritation of sulforaphane in the above-mentioned existing products, thereby perfectly solving the above-mentioned technical problems.
[0014] Based on this discovery, in the first aspect of the present invention, a non-irritating solid nutritional targeting composition for effectively releasing sulforaphane is provided, wherein the solid composition comprises the following components: (1) providing component 1 of glucoraphanin; (2) providing component 2 of myrosinase; and (3) α-cyclodextrin.
[0015] In the present invention, the component 1 providing glucoraphanin can be any substance or raw material that can provide a source of glucoraphanin compounds. Preferably, the component 1 providing glucoraphanin is selected from cruciferous plants, extracts thereof and mixtures thereof. The cruciferous plants are preferably selected from broccoli, cauliflower, red cabbage, Brussels sprouts or cabbage, and broccoli is particularly preferred. The cruciferous plants can be all or part of the plant, such as the whole plant, its aerial parts, flower heads, sprouts, seeds or a combination thereof. The component 1 providing glucoraphanin can also be an extract of the cruciferous plant, such as a solvent extract, preferably a water extract, an alcohol extract, a hydroalcoholic extract. In addition to plant tissues, extracts and mixtures thereof of cruciferous plants, the component 1 providing glucoraphanin of the present invention can also include chemically synthesized, semi-chemically synthesized, enzymatically synthesized or biosynthesized glucoraphanin.
[0016] In the present invention, the component 2 providing myrosinase can be any suitable substance or raw material that can provide a source of myrosinase. Preferably, the component 2 providing myrosinase is selected from cruciferous plants, extracts thereof and mixtures thereof. Preferably, the component 2 providing myrosinase is selected from horseradish, radish and cabbage. In some preferred embodiments, the component 2 providing myrosinase is selected from extracts of horseradish, radish and cabbage; in other preferred embodiments, the component 2 providing myrosinase is selected from the juice or slurry of horseradish, radish and cabbage, or the powder obtained by drying the juice or slurry.
[0017] In the present invention, the broccoli refers to the whole or part of the broccoli plant. Preferably, the broccoli is selected from edible parts in the usual sense; more preferably, the broccoli is selected from broccoli heads, broccoli seeds and broccoli sprouts, and combinations thereof.
[0018] In the present invention, the broccoli extract refers to an extract of the whole or a part of the broccoli plant, including but not limited to extracts of the broccoli, broccoli florets, broccoli seeds and / or broccoli sprouts. On the other hand, the extract is an extract obtained by extraction using a solvent, and the extract is preferably a water extract, an alcohol extract or a hydroalcoholic extract, and particularly preferably a water extract.
[0019] In the present invention, the component 1 providing glucoraphanin is preferably selected from broccoli florets, broccoli seeds, broccoli sprouts, broccoli extracts and mixtures thereof, and chemically synthesized or biosynthesized glucoraphanin.
[0020] In the present invention, the mass ratio of component 1, component 2 and α-cyclodextrin is (10-80):(1-80):(5-60); preferably (10-40):(1-40):(5-30), and more preferably (10-30):(1-10):(5-15).
[0021] The solid composition of the present invention may be in the form of a powder, granule, capsule or tablet. More preferably, in the composition of the present invention, the component 1, component 2 and α-cyclodextrin are all present in solid form. For example, the component 1 may be in the form of a powder (including lyophilized powder) of an extract, sprout or seed; the component 2 may be in the form of a dry powder or a dry extract (including lyophilized powder).
[0022] In some preferred embodiments, component 1 of the present invention is selected from broccoli seed extract, broccoli sprout powder, broccoli floret freeze-dried powder and mixtures thereof.
[0023] In another aspect, the present application provides a use of the nutritional targeting composition of the present invention in the preparation of a product for preventing and / or treating a disease or condition that can be prevented and / or treated with sulforaphane. The product may be a medicine or a food. Preferably, the product is a medicine. In some preferred embodiments, the disease or condition that can be prevented and / or treated with sulforaphane is selected from cancer, diabetes, cardiovascular disease, Helicobacter pylori infection, autism, schizophrenia, depression, Alzheimer's disease (AD) and pulmonary fibrosis.
[0024] In another aspect, the present application provides a method for converting glucoraphanin into sulforaphane in vitro, comprising the following steps: 1) providing a solid composition according to the present invention, 2) Mixing the composition with water or an aqueous solution.
[0025] In another aspect, the present application also provides a method for supplementing sulforaphane to a subject in need thereof, comprising administering the composition of the present invention to the subject.
[0026] In another aspect, the present application provides a method for preparing a product that can release sulforaphane when dissolved in water and reduce irritation to the oral cavity and stomach, comprising the step of mixing component 1 providing glucoraphanin, component 2 providing myrosinase, and α-cyclodextrin.
[0027] The present inventors unexpectedly discovered that by adding α-cyclodextrin to the composition, it is possible to effectively achieve successful release of sulforaphane when mixed with water or an aqueous solution for administration while reducing its gastric irritation without affecting the release of sulforaphane. DETAILED DESCRIPTION Example 1 : Preparation of the composition of the present invention (powder) and the control composition (powder)
[0028] Preparation of the composition of the present invention: 600 g of broccoli seed water extract (containing 13.0% glucoraphanin, from Brassica Protection Products LLC, USA, hereinafter the same), 60 g of horseradish powder (myrosinase 30 u / mg, hereinafter the same) and 300 g of α-cyclodextrin were mixed uniformly to obtain 0.96 kg of composition 1, in which glucoraphanin accounted for 8.13%. The above composition was divided into small bags with a weight of 5 g per bag to obtain the corresponding powder product (the composition of the present invention).
[0029] Preparation of the control composition: 600 g of broccoli seed water extract (containing 13.0% glucoraphanin), 60 g of horseradish powder and 300 g of starch were mixed evenly to obtain 0.96 kg of composition 2, in which glucoraphanin accounted for 8.13%. The above composition was packed into small bags at a weight of 5 g per bag to obtain the corresponding powder product (control composition).
[0030] 1 g of each of the two powder products was taken and dissolved in 40 ml of water at 37° C. to react and generate sulforaphane. Samples were taken at 60 minutes, and the content of sulforaphane in the aqueous solution was determined by HPLC, and the generation rate of sulforaphane was calculated.
[0031] HPLC determination method of sulforaphane: Take the sample solution, pass it through a 0.45μm filter membrane, and perform HPLC analysis. HPLC conditions: chromatographic column: Huapu Unitary C18 (4.6mm×250mm, 5μm); column temperature: 30℃; mobile phase: 70% water-30% acetonitrile; flow rate: 0.8mL / min; injection volume: 10μL; UV detection wavelength: 245nm.
[0032] The two reaction solutions were freeze-dried to obtain powders containing sulforaphane and sulforaphane α-cyclodextrin inclusion complex.
[0033] 0.100 g of the two powders were taken and washed with 50 ml of dichloromethane to remove the unincluded sulforaphane on the surface of the powders, and then the unincluded sulforaphane content in the washing solution was detected by HPLC. Another 0.100 g of the two powders were taken and dissolved in 50 ml of water, and the sulforaphane content in the aqueous solution was detected by HPLC. The sulforaphane content of 0.100 g of the powder was calculated, and then the sulforaphane inclusion rate was calculated (sulforaphane inclusion rate % = (1-sulforaphane content in washing solution / sulforaphane content in sampled powder) × 100%).
[0034] The experimental results are shown in Tables 1 and 2 below. Table 1 Comparison of sulforaphane release from the powder products of the composition of the present invention and the control composition Table 2 Comparison of sulforaphane inclusion rates of the powder products of the composition of the present invention and the control composition Powder Group Sulforaphane inclusion rate (%) Inventive composition 98.1% Control composition 7.8% Example 2 : Preparation of the composition (tablet) of the present invention and the control composition (tablet)
[0035] Preparation of the composition of the invention: 300 g of broccoli seed water extract, 30 g of horseradish powder, 150 g of α-cyclodextrin and 450 g of other tableting excipients were mixed evenly, tableted at a tablet weight of 1 g / tablet, and film-coated to obtain about 0.93 kg of the tablets of the invention, in which glucoraphanin accounted for 4.19%. The above composition was divided into bottles at a rate of 60 tablets per bottle, and the bottle mouth was sealed after adding a desiccant to obtain the corresponding tablet product (the composition of the invention).
[0036] Preparation of control composition: 300g of broccoli seed water extract, 30g of horseradish powder, 150g of starch and 450g of other tableting excipients were mixed evenly, tableted at a tablet weight of 1g / tablet, and film-coated to obtain about 0.93kg of control tablets, of which glucoraphanin accounted for 4.19%. The above composition was packed into bottles at 60 tablets per bottle, and the bottle mouth was sealed after adding a desiccant to obtain the corresponding tablet product (control composition).
[0037] 2 g of each of the two tablet products was taken and dissolved in 40 ml of water at 37° C. to react and generate sulforaphane. Samples were taken at 60 minutes, and the content of sulforaphane in the aqueous solution was determined by HPLC, and the generation rate of sulforaphane was calculated.
[0038] HPLC determination method of sulforaphane: Take the sample solution, pass it through a 0.45μm filter membrane, and perform HPLC analysis. HPLC conditions: chromatographic column: Huapu Unitary C18 (4.6mm×250mm, 5μm); column temperature: 30℃; mobile phase: 70% water-30% acetonitrile; flow rate: 0.8mL / min; injection volume: 10μL; UV detection wavelength: 245nm.
[0039] The two reaction solutions were freeze-dried to obtain powders containing sulforaphane and sulforaphane α-cyclodextrin inclusion complex.
[0040] 0.100 g of the two powders were taken and washed with 50 ml of dichloromethane to remove the unincluded sulforaphane on the surface of the powders, and then the unincluded sulforaphane content in the washing solution was detected by HPLC. Another 0.100 g of the two powders were taken and dissolved in 50 ml of water, and the sulforaphane content in the aqueous solution was detected by HPLC. The sulforaphane content of 0.100 g of the powder was calculated, and then the sulforaphane inclusion rate was calculated (sulforaphane inclusion rate % = (1-sulforaphane content in washing solution / sulforaphane content in sampled powder) × 100%).
[0041] The experimental results are shown in Tables 3 and 4 below. Table 3 Comparison of sulforaphane release in tablet products of the composition of the present invention and the control composition Powder Group 60min sulforaphane release rate (%) Inventive composition 61.9% Control composition 61.1% Table 4 Comparison of sulforaphane inclusion rates of tablet products of the composition of the present invention and the control composition Powder Group Sulforaphane inclusion rate (%) Inventive composition 98.5% Control composition 8.0%
[0042] Examples 3-4 In another group of examples, the composition (powder and tablet) of the present invention was prepared as in Example 1, except that the ratio of components was different (300 g broccoli seed water extract: 100 g horseradish powder: 150 g α-cyclodextrin). The release rate and inclusion rate of sulforaphane were tested using the same method and conditions as in Example 1, and similar results were obtained, i.e., the inclusion rate was significantly better than that of the control composition without α-cyclodextrin, while the release rate of sulforaphane was not affected.
[0043] From the experimental results, it can be seen that compared with the control composition without α-cyclodextrin, the sulforaphane inclusion rate of the invention composition containing α-cyclodextrin is significantly improved, up to more than 10 times; on the other hand, the sulforaphane content released by the two is similar, that is, the sulforaphane release rate is not affected. When the invention composition containing α-cyclodextrin and the control composition without α-cyclodextrin are taken with water, it is found that the irritation to the oral cavity and stomach of the invention composition containing α-cyclodextrin is significantly reduced, which indicates that α-cyclodextrin can include sulforaphane released by the composition containing glucoraphanin and myrosinase in water, reduce its irritation to the human oral cavity and stomach, and does not affect the release of sulforaphane. Such a result is unexpected.
[0044] It should be understood that, although the present invention is specifically disclosed by preferred embodiments, those skilled in the art may adopt the optional features, modifications, improvements and variations of the present invention embodied by the content disclosed herein, and it is considered that these modifications, improvements and variations are within the scope of the present invention. The materials, methods and embodiments provided herein as exemplary preferred example schemes are exemplary and are not intended to limit the scope of the present invention.
Claims
1. A solid composition comprising the following components: 1) providing component 1 of glucoraphanin; 2) providing component 2 of myrosinase; and 3) α-cyclodextrin.
2. The composition of claim 1, wherein the component 1 is selected from the group consisting of cruciferous plants, extracts thereof, and mixtures thereof.
3. The composition of claim 2, wherein the cruciferous plant is broccoli.
4. The composition according to any one of claims 2 to 3, wherein the cruciferous plant is selected from the group consisting of curds, seeds, sprouts and mixtures thereof.
5. The composition according to any one of claims 1 to 4, wherein the mass ratio of component 1, component 2 and α-cyclodextrin is (10-80):(1-80):(5-60).
6. The composition according to any one of claims 1 to 5, which is in the form of a powder, granules, capsule or tablet.
7. The composition according to any one of claims 1 to 6, wherein the component 1 is selected from broccoli seed extract, broccoli sprout powder, broccoli curd freeze-dried powder and mixtures thereof, and chemically synthesized or biosynthesized glucoraphanin.
8. The composition of any one of claims 1 to 7, wherein the component 2 is selected from horseradish, radish, cabbage; juice or serum thereof; and extracts thereof.
9. Use of the composition of any one of claims 1 to 8 in the preparation of a product for preventing or treating a disease or condition that can be prevented or treated with sulforaphane.
10. The use according to claim 9, wherein the disease or condition that can be prevented or treated by sulforaphane is selected from cancer, diabetes, cardiovascular disease, Helicobacter pylori infection, autism, schizophrenia, depression, Alzheimer's disease and pulmonary fibrosis.
11. A method for converting glucoraphanin into sulforaphane in vitro, comprising the following steps: 1) Providing a composition according to any one of claims 1 to 8, 2) Mixing the composition with water or an aqueous solution.
12. A method of supplementing sulforaphane to a subject in need thereof, comprising administering to the subject the composition of any one of claims 1 to 8.
13. A method for preparing a product that can release sulforaphane when dissolved in water and reduce irritation to the oral cavity and stomach, comprising the step of mixing component 1 providing glucoraphanin, component 2 providing myrosinase and α-cyclodextrin.
Citation Information
Patent Citations
Methods of suppressing UV light-induced skin carcinogenesis
CN101208079B
Compounds derived from sulforaphane, processes for their preparation and their medical, food and cosmetic uses
CN104284885B
Method for producing chemiprotectant crucifer germplasm
CN1170472C
Chemoprotectants from crucifer seeds and sprouts
CN1935003A
Cited By
Solid beverage preparation process capable of improving glucoraphanin conversion rate
CN119999840A
